Oscar Health Trading at a Premium: Why Should You Still Buy It?

Oscar Health membership rose 46% year over year to 2.96 million by June 30, 2026, while Q2 revenue increased 70% to $4.88 billion. Management forecasts 2026 revenue of $18.7-$19.0 billion, targets 20% revenue CAGR through 2027 and a 5% operating margin next year; shares are up 142.5% year to date. The article views growth, improving cost ratios and raised profit expectations as support for the stock, while noting its 4.65 price-to-book multiple exceeds the 2.65 industry average.

Analysis

The key issue is not whether Oscar can grow, but whether growth converts into durable underwriting returns. A larger ACA book can amplify earnings in both directions: adverse selection, medical-cost trend, or risk-adjustment transfers can quickly overwhelm operating leverage. The 5% operating-margin target therefore matters more than headline enrollment or revenue growth; the premium multiple is vulnerable if margin progress depends on temporary risk-adjustment relief rather than repeatable pricing and claims performance.

Near term, the sharp rerating raises the bar for further positive surprises. Over the next 1–3 months, watch rate filings, subsidy policy signals and quarterly MLR/risk-adjustment disclosures; any indication that pricing is lagging medical costs could unwind the earnings narrative. Over 6–18 months, entry into additional markets offers scale potential but also increases provider-network and local pricing execution risk. Larger incumbents such as Centene and Molina may defend ACA share with broader operating footprints, though their Medicaid exposure makes them imperfect comparables and imperfect hedges.

Contrarian read: the technology/platform narrative may be receiving credit before it is independently visible in sustained returns on capital. The article’s growth and margin targets are management/analyst expectations, not proof that new-market economics will match the existing book. There is no basis here to quantify fair value or assert the premium is unjustified; validate operating margin, MLR, risk-adjustment effects, and membership retention before underwriting it.

Key Decisions for Investors

• Avoid chasing OSCR after its large rerating; treat it as a watch/hold until reported results demonstrate that MLR and operating-margin improvement persist without relying on favorable risk-adjustment effects.
• For an existing OSCR position, consider reducing exposure or using a defined-risk hedge into upcoming earnings and policy catalysts. Reassess if operating-margin progress stalls, MLR deteriorates, or guidance is cut; the 5% margin target is the key thesis checkpoint.
• A modest relative-value short OSCR / long Centene position is a possible valuation-and-momentum hedge, not a pure pair: size conservatively because Centene has materially different Medicaid exposure. Revisit if OSCR’s unit economics confirm durable returns or the ACA outlook weakens for both.
• Before initiating a fresh long, verify rate adequacy, risk-adjustment net impact, retention, and per-member economics in newly entered markets. Favor the thesis only if margin expansion is supported by repeatable underwriting performance, not enrollment growth alone.